Sequential combination therapy of CDK inhibition and doxorubicin is synthetically lethal in p53-mutant Triple-negative breast cancer

Natalie A. Jabbour-Leung, Xian Chen, Tuyen Bui, Yufeng Jiang, Dong Yang, Smruthi Vijayaraghavan, Mark J. McArthur, Kelly K. Hunt, Khandan Keyomarsi

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Fingerprint

Dive into the research topics of 'Sequential combination therapy of CDK inhibition and doxorubicin is synthetically lethal in p53-mutant Triple-negative breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences